Cerus Corporation (Nasdaq: CERS) announced today the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Total proceeds for the offering were $63.3 million, before deducting estimated offering expenses payable by Cerus.
BTIG, LLC acted as sole book-running manager for the offering.
A shelf registration statement on Form S-3 (File No. 333-219727) relating to the shares of common stock described above was previously filed by Cerus with the Securities and Exchange Commission ("SEC") and declared effective on January 8, 2018. You should read the prospectus in the registration statement and related final prospectus supplement that Cerus has filed with the SEC for complete information about Cerus and this offering. A final prospectus supplement and accompanying prospectus relating to the offering is available on the SEC's website located at http://www.sec.gov. Alternatively, copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting BTIG, LLC at 65 East 55th Street, New York, NY, 10022, by email at email@example.com or by telephone at (212) 593-7555.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply. Based in Concord, California, Cerus develops and markets the INTERCEPT Blood System. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.